United Therapeutics Corp (UTHR) Com Stk USD0.01

Sell:$448.87Buy:$449.23$6.93 (1.53%)

NASDAQ:0.22%
Market closed |
Prices delayed by at least 15 minutes
Sell:$448.87
Buy:$449.23
Change:$6.93 (1.53%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:$448.87
Buy:$449.23
Change:$6.93 (1.53%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

Key people

Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Michael Benkowitz
President, Chief Operating Officer
James C. Edgemond
Chief Financial Officer, Treasurer
Paul A. Mahon
Executive Vice President, General Counsel, Corporate Secretary
Christopher Patusky
Lead Independent Vice Chairman of the Board
Jan Malcolm
Director
Christopher A. Causey
Independent Director
Raymond A. Dwek
Independent Director
Richard A. Giltner
Independent Director
Click to see more

Key facts

  • Shares in issue
    75.86m
  • EPIC
    UTHR
  • ISIN
    US91307C1027
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $19.27bn
  • Employees
    1,305
  • Exchange
    NASDAQ
  • Index
    S&P 400 Mid Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.